Tech Center 1600 • Art Units: 1648 1671 1672
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17639442 | Self-Assembling Protein Nanostructures Displaying Paramyxovirus and/or Pneumovirus F Proteins and Their Use | Final Rejection | UNIVERSITY OF WASHINGTON |
| 17632542 | METHODS AND COMPOSITIONS FOR STABILIZED RECOMBINANT FLAVIVIRUS E PROTEIN DIMERS | Non-Final OA | The University of North Carolina at Chapel Hill |
| 17050115 | INDICATOR BACTERIOPHAGE FOR SELECTING AND MONITORING FOR EFFICACY OF THERAPEUTICS AND METHODS FOR USING SAME | Non-Final OA | LABORATORY CORPORATION OF AMERICA HOLDINGS |
| 18347698 | SELF-AMPLIFYING RNA ENCODING AN INFLUENZA VIRUS ANTIGEN | Non-Final OA | PFIZER INC. |
| 18045967 | RNA MOLECULES | Non-Final OA | Pfizer Inc. |
| 18318842 | DELIVERY OF BIOMOLECULES TO PBMCs TO MODIFY AN IMMUNE RESPONSE | Non-Final OA | STEMCELL TECHNOLOGIES CANADA INC. |
| 17563780 | FORMULATIONS OF ACTIVATING ANTIGEN CARRIERS | Non-Final OA | STEMCELL TECHNOLOGIES CANADA INC. |
| 17761459 | HUMAN RESPIRATORY SYNCYTIAL VIRUS STRAIN AND ITS USE | Final Rejection | UNIVERSITEIT ANTWERPEN |
| 18024868 | VACCINE FOR VIRAL PATHOGENS | Non-Final OA | THE UNIVERSITY OF BRITISH COLUMBIA |
| 17802936 | COMPOSITIONS COMPRISING SELF-ASSEMBLING VACCINES AND METHODS OF USING THE SAME | Non-Final OA | The Wistar Institute of Anatomy and Biology |
| 18418050 | MULTI-CBV VACCINE FOR PREVENTING OR TREATING TYPE I DIABETES | Non-Final OA | Vactech Oy |
| 18044245 | FUSION PROTEIN COMPRISING CORONAVIRUS-DERIVED RECEPTOR-BINDING DOMAIN AND NUCLEOCAPSID PROTEIN, AND USE THEREOF | Non-Final OA | GI CELL, INC. |
| 18261811 | INFORMATION PROVISION METHOD FOR EXAMINING ACTIVE IMMUNITY BY USING PRODUCTION OF NEUTRALIZING ANTIBODIES AND INTERFERON GAMMA | Non-Final OA | BODITECH MED INC. |
| 17621125 | ATTENUATED DENGUE VIRUSES | Non-Final OA | CODAGENIX INC. |
| 17997434 | SARS-COV-2 VIRAL PROTEINS AND USE THEREOF | Non-Final OA | Institut Pasteur |
| 17907424 | DEFECTIVE INTERFERING VIRAL GENOMES | Non-Final OA | INSTITUT PASTEUR |
| 18266486 | USE OF VACCINE COMPOSITIONS BASED ON SARS-COV-2 RECEPTOR BINDING DOMAIN IN DELIVERING PROTECTIVE IMMUNITY | Non-Final OA | Centro de Inmunología Molecular |
| 18021731 | COMPOSITIONS OF SARS-COV-2 VACCINES BASED ON THE RECEPTOR BINDING DOMAIN, EXPRESSED AS A DIMER, AND THE OUTER MEMBRANE VESICLE OF MENINGOCOCCAL GROUP B BACTERIA | Non-Final OA | Centro de Inmunología Molecular |
| 18265008 | DIAGNOSTIC TESTING | Non-Final OA | PARAYTEC LTD |
| 18038673 | YEAST-BASED EXPRESSION OF THERAPEUTIC PROTEINS IN VIVO | Non-Final OA | ESPEROVAX INC. |
| 17907532 | METHODS TO GENERATE VACCINE COMPOSITIONS THAT PRIME HUMAN LEUKOCYTE ANTIGEN CLASS I RESTRICTED CD8 T-CELL RESPONSES AGAINST VIRAL NON-VIRION-INTEGRAL DERIVED EPITOPES | Non-Final OA | Genovie AB |
| 18312939 | LYME RELATED INFECTION INDICATOR | Final Rejection | DR RP HOLDINGS, LLC |
| 17838114 | DURABLE VACCINATION | Non-Final OA | Gritstone bio, Inc. |
| 17877986 | Buffer Free, Acid Stable Low Dose Volume Rotavirus Vaccine | Final Rejection | Bharat Biotech International Limited |
| 18020659 | PROTEINS, POLYNUCLEOTIDES, AND METHODS FOR TREATING CORONAVIRUS INFECTION | Non-Final OA | WESTPORT BIO, LLC |
| 18004517 | ENHANCING IMMUNE RESPONSES THROUGH TARGETED ANTIGEN EXPRESSION | Non-Final OA | PhageNova Bio, Inc. |
| 18009714 | VACCINE COMPOSITIONS, METHODS, AND USES THEREOF | Non-Final OA | Sichuan Clover Biopharmaceuticals, Inc. |
| 17801110 | IgG VARIANTS FOR INDUCTION OF IMMUNE RESPONSE WITHOUT ADJUVANT | Final Rejection | ARIZONA BOARD OF REGENTSON BEHALF OF ARIZONA STATE UNIVERSITY |
| 17615661 | SMALLPOX VACCINE AND STEM CELLS FOR TREATMENT OF DISEASE | Final Rejection | IMMUNOLUX INTERNATIONAL CORP. |
| 17612560 | METHODS AND COMPOSITIONS OF ASTROVIRUS REPLICONS | Final Rejection | ACCESS TO ADVANCED HEALTH INSTITUTE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy